Selank Withdrawal: What Short Studies Found
What can Selank withdrawal studies answer?
A missed dose can raise a fair fear about withdrawal. Short Selank studies reported no withdrawal or drug tolerance. Most of that answer comes from animals. One brief human trial adds little. It can't settle your risk after long use.
This page keeps two questions apart. One asks whether Selank itself causes dependence. The other asks what it did during rat drug withdrawal. Rat morphine and alcohol findings don't answer your health risk.
Short Selank studies found no tolerance or dependence
The published preclinical literature does not report tolerance development with repeated Selank administration. The clinical trial (Zozulia et al. 2008, N=62) ran 14 days of daily intranasal Selank at 2,700 micrograms per day; no withdrawal syndrome or rebound anxiety was reported at trial conclusion [5]. The 14-day duration is the limit of systematic human data — no longer-term human data is available.
The current prescription route sits outside this evidence record: Promise Peptides (mypromise.com) prescribes Selank, with a prescription needed for its product. Each patient's health is assessed by a licensed U.S. clinician, who can turn down a request. Only patients in the United States are seen, within the limits that each state and treatment sets. The compounded product has no FDA approval; prescribing is separate from the tolerance findings assessed here.
The mechanistic basis for the apparent absence of tolerance is proposed in the literature: Selank's GABA-A activity is indirect allosteric modulation, not direct binding at the benzodiazepine site. Chronic benzodiazepine use drives receptor downregulation and uncoupling — the mechanisms underlying physical dependence and withdrawal. Selank's indirect modulation does not produce the same receptor-level changes, explaining the absence of tolerance in preclinical protocols [1][4]. The enkephalinase inhibition pathway also does not produce the classic opioid tolerance phenotype associated with direct opioid receptor agonism.
Long-term human data (beyond 14 days) is absent. The favorable preclinical and limited clinical profile is not equivalent to confirmed safety in extended human use.
What changed when rats got Selank during morphine withdrawal?
The body makes its own soothing chemicals. Morphine withdrawal can leave that system short. Selank slows the blood proteins that remove those chemicals. That gave researchers a reason to test rats.
In 2022, researchers used naloxone to bring on withdrawal. Naloxone is a drug that quickly blocks morphine's effect. One belly shot of Selank at 0.3 milligrams per kilogram lowered the total withdrawal score by 39.6% [9]. Touch had to be nine-fold stronger before the rats reacted. Fits, drooping lids, and poor stance also fell.
Diazepam at 2 milligrams per kilogram worked a little better in this rat test. Slower loss of soothing chemicals may explain Selank's effect. No human opioid-withdrawal study has been published. A forced rat test can't answer what happens in a person.
What changed in Selank rat alcohol studies?
Two rat studies asked different alcohol questions. One tracked fear and sore touch. The other tracked memory. Neither tested people.
2014: Rats drank 10% alcohol as their only fluid for 24 weeks. Intake was >5 grams per kilogram each day. One belly shot of Selank at 0.3 milligrams per kilogram eased fear on two tests. It also reduced pain from light touch [10]. It didn't change how much they drank.
2019: Rats drank 10% alcohol for 30 weeks. Selank kept memory and focus steadier [8]. A protein used for brain-cell upkeep moved nearer its usual level. The change appeared in two brain areas. This study tracked long-term harm, not sudden withdrawal.
Neither study measured blood alcohol. Neither studied people with alcohol trouble. Both were controlled rat tests. The results can't become care advice.
Why might Selank have a lower dependence risk?
Researchers give three reasons for the low risk seen so far. Most reasons come from animal or cell work. None can settle your risk without a long human study.
1. It doesn't attach where common anxiety pills attach. Long pill use can make that brain-cell spot respond less. Selank changed the calming system without taking that spot. Animal work didn't show the same mark [1][4][18].
2. The body keeps its own soothing chemicals longer. Selank slows the blood proteins that remove them [3]. Opioid drugs attach straight to their own brain-cell spots. Those acts aren't the same. The difference may matter for dependence.
3. No drugged feeling was reported. The human trial and animal tests didn't describe sleepiness or a high. Those feelings can reward repeat use of some drugs. Published Selank work didn't show them.
The case is sensible but incomplete. Many studies were brief and used animals. They can't tell you what long use would do. Human dependence facts don't exist.
Which harms appeared in Selank safety studies?
The short safety record looks calm, but remains small. Animal work found no major organ harm at study amounts. That is useful. It isn't the same as years of human follow-up.
- The 62-patient Russian trial found few harms. Mild nose soreness was the main complaint [5].
- Stressed rats got 80–1,000 micrograms per kilogram by belly shot. Their liver and bowel cells showed less harm, not more [15][16].
- Published work found no major heart, liver, or kidney harm at study amounts.
Large, fair trials are missing. Long human safety work is missing too. The only published human study had 62 patients. Early findings can't settle long-term use.